# Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial Tablets

> **NCT04314024** · PHASE1 · COMPLETED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Evobrutinib

## Key facts

- **NCT ID:** NCT04314024
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-25
- **Primary completion:** 2020-06-23
- **Final completion:** 2020-06-23
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2020-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04314024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04314024, "Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial Tablets". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04314024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*